Diabetes is a chronic condition caused by the body’s inability to produce or make use of insulin
Disease awareness section where you can access information and resources to educate and motivate people living with diabetes
Obesity has been recognised by health organisations including the WHO as a chronic disease that requires long-term management
Haemophilia is an inherited (congenital) bleeding disorder that affects males
Growth Hormone is crucial to the healthy development and functioning of the human body
HRT is used to treat climacteric symptoms of women in different stages of the menopause
Board of Directors and Executive Management
How we are managed, directed and controlled
Semaglutide receives positive 16-0 vote in favour of approval from FDA Advisory ... Read more
Novo Nordisk: FDA posts briefing materials prior to Advisory Committee meeting f ... Read more
Novo Nordisk's new fast-acting mealtime insulin Fiasp® approved in the US ... Read more
CHMP endorses Tresiba® label update in the EU - new label reflects significant r ... Read more
Novo Nordisk A/S - Share repurchase programme ... Read more
Financial statement for the first nine months of 2017,
Societe Generale European ESG/SRI Conference, Paris
HSBC Healthcare Conference, Frankfurt
Dansk Aktionærforening - InvestorDagen, Vejle
Take an advanced view of the Novo Nordisk share
Click here to find further information
Semaglutide AdCom conference call and roadshow presentation
Read about Novo Nordisk – A focused healthcare company
See relevant content for private investors
Download relevant Investor Relations material
Peter Hugreffe AnkersenHead of Investor Relations
Hanna Ögren Investor Relations Manager
Anders Mikkelsen Investor Relations Manager
Christina Kjær Investor Relations Manager
Kasper Veje Associate Director IR, North America
Chilie Thomsen Investor Relations Coordinator
Sign up to receive company announcements.
LEADER AdCom conference call and presentation
